Pfizer Inc. (NYSE: PFE) is set to showcase significant advancements in its hematology and breast cancer portfolios at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). The company will present data from over 100 abstracts, including 13 oral presentations and four poster spotlights, on both its approved medicines and promising new therapies for blood and breast cancers, as well as rare blood disorders.
“Our strong presence at ASH and SABCS highlights Pfizer’s continued commitment to innovation in blood disorders and breast cancer,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “We are excited to share the latest results for key approved treatments like ADCETRIS, ELREXFIO, and IBRANCE, as well as new data from our growing pipeline, including novel combination therapies for both blood and breast cancers.”
Key ASH Presentations
Pfizer will present data from more than 75 research abstracts at ASH, including pivotal findings from the ECHELON-3 trial supporting ADCETRIS® (brentuximab vedotin) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Additionally, data from the pivotal MagnetisMM-3 trial will showcase the efficacy of ELREXFIO® (elranatamab-bcmm) in relapsed/refractory multiple myeloma (RRMM).
Key highlights include:
- ADCETRIS: New analyses from the Phase 3 ECHELON-3 trial demonstrate durable complete responses and consistent benefits in patients with relapsed/refractory DLBCL, even in elderly patients or those with prior CAR-T therapy.
- ELREXFIO: Post hoc analysis of the MagnetisMM-3 trial continues to show long-term responses, and the ongoing MagnetisMM-20 trial will present data on its combination with carfilzomib and dexamethasone in RRMM.
- SEA-CD70: Encouraging early-phase data will be shared on SEA-CD70, an investigational drug targeting CD70, in combination with azacitidine for high-risk myelodysplastic syndromes (MDS).
Key SABCS Presentations
Pfizer will present data from 30 research abstracts at SABCS, including results reinforcing IBRANCE® (palbociclib) as a first-line treatment for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). The company will also present new data on its next-generation breast cancer therapies.
Key highlights include:
- IBRANCE: Real-world data from the P-VERIFY study show consistent survival outcomes across CDK4/6 inhibitor groups in HR+/HER2- MBC.
- Atirmociclib: Updated Phase 1/2a data will be presented from a study of atirmociclib, a highly selective CDK4 inhibitor, in combination with letrozole as a first-line treatment for HR+/HER2- MBC.
- Vepdegestrant: Initial Phase 1b data from the TACTIVE-U trial will be shared, evaluating vepdegestrant, a first-in-class estrogen receptor degrader, in combination with abemaciclib for HR+/HER2- MBC.
- KAT6: New data from a Phase 1 expansion study of PF-07248144, a KAT6 inhibitor, will provide evidence for this novel approach to treating ER+/HER2- MBC.
These presentations underscore Pfizer’s ongoing efforts to expand treatment options for patients with blood and breast cancers, offering innovative solutions for some of the most challenging unmet needs in oncology.
